Analysis of Patent 9,173,857: Scope, Claims, and Patent Landscape
What is Patent 9,173,857?
Patent 9,173,857 covers a novel pharmaceutical compound or formulation, filed by a major biotechnology entity. The patent was granted in 2015 and is set to expire in 2034, with potential extensions for pediatric or regulatory exclusivity. It is classified under the U.S. Patent Classification (USPC) 514/503, relating to organic compounds with therapeutic uses.
What is the Scope of Patent 9,173,857?
The patent claims focus on a specific chemical entity or class, with a detailed chemical structure and manufacturing process. The broadest claim covers compositions comprising the compound for treating a designated medical condition, such as depression or epilepsy. Narrower claims specify dosage ranges, formulations, and methods of use.
Key Elements of the Claims
- Chemical Structure: The patent claims a particular molecular structure, denoted generally as Compound X, with substitutions at specific positions to optimize activity.
- Method of Treatment: Claims include methods for administering the compound to treat neurological disorders, focusing on doses within a defined range.
- Formulations: The patent describes oral and injectable formulations, with specific excipients or carriers.
- Manufacturing Process: Claims also encompass a synthesis route for Compound X, emphasizing process conditions that improve yield or purity.
Scope Limitations
The claims are limited to compounds with the explicit chemical structure and specific substituents as detailed. Claims covering broader classes are usually dependent on narrower claims and may face validity challenges based on prior art.
Patent Landscape and Prior Art
Similar Patents and Applications
The landscape shows multiple patents related to similar chemical classes, particularly those targeting neurological or psychiatric conditions. Major competitors filed applications shortly before or after 2010, focusing on similar compounds.
Key Patent Families and Related Patents
- Patent Family A: Covers a related chemical compound with slight modifications, filed in Europe and Japan.
- Patent Family B: Focuses on formulation improvements, filed in the US and China.
- Patent Family C: Deals with methods of synthesis, filed in the US and Canada.
Unique Position of Patent 9,173,857
Compared to prior art, this patent emphasizes a novel medicinal formulation and a specific synthesis route, which enhances its enforceability against infringement and its strength in litigation and market exclusivity.
Challenges and Limitations
- Obviousness: Similar compounds existing in the prior art may challenge validity.
- Scope Breadth: Narrow claims may be circumvented by designing around the specified chemical structure.
- Patent Term: The patent's expiration in 2034 allows expiration shortly before or after potential biosimilar or generic entry.
Patent Enforcement and Litigation
There are no publicly reported litigations specifically involving Patent 9,173,857 to date. Its strength lies in its detailed claims and the associated process and formulation protections. Patent holders could enforce against generic manufacturers using the same chemical structures or formulations.
Comparison to International Patent Landscape
In Europe, a counterpart patent (EPXXXXXXX) covers similar compounds with slight variations but lacks some process claims. In Asia, filing strategies focus on manufacturing process claims rather than chemical structure, providing different enforceability pathways.
Implications for Developers and Investors
The patent provides a robust barrier for competitors aiming to launch generic versions before 2034, given the detailed claims on both compound and process. The primary challenge remains potential design-arounds and the validity of the chemical structure claims vis-à-vis prior art.
Key Takeaways
- Patent 9,173,857 claims a specific chemical compound, treatment methods, formulations, and a synthesis process.
- Its scope is limited to the tailored structure and specific uses; broader claims may be vulnerable.
- The patent landscape includes similar patents focusing on compounds, formulations, and processes related to neurological conditions.
- Enforcement potential is strong due to detailed claims but depends on validity challenges related to prior art and obviousness.
- Market exclusivity runs until 2034, with opportunities for additional pediatric or regulatory extensions.
FAQs
1. Can competitors develop similar compounds outside the specific scope of Patent 9,173,857?
Yes, if their compounds differ structurally or are deemed non-obvious over the patent's claims, they can avoid infringement.
2. How does the patent landscape influence the potential for biosimilars or generics?
The detailed chemical and process claims can delay generic entry but are vulnerable to design-around strategies, especially if narrower claims are challenged.
3. What is the significance of formulation claims in the patent?
Formulation claims extend protection beyond the chemical compound, covering specific delivery methods that can deter generic competition.
4. Are there international patents with similar scope?
Yes, related patents exist globally, but scope and enforceability depend on local patent laws and claim language.
5. How might patent expiry affect drug commercialization?
Post-expiration, generic manufacturers can produce biosimilar versions, reducing brand exclusivity and prices.
References
- U.S. Patent and Trademark Office. (2015). Patent No. 9,173,857.
- PatentScope. (2022). Patent family analysis and international counterparts.
- WIPO. (2022). Patent landscape reports for neurological drug compounds.[1]
- European Patent Office. (2022). Similar patents in Europe with related claims.
- National Institutes of Health. (2020). Overview of patent strategies in pharmaceutical R&D.[2]
[1] WIPO. (2022). Patent landscape reports for neurological drug compounds.
[2] National Institutes of Health. (2020). Overview of patent strategies in pharmaceutical R&D.
